Trials / Completed
CompletedNCT00303108
Doxil & Carboplatin Plus HER2+ in Metastatic Breast Cancer
Phase II Study of Doxil and Carboplatin, Plus Herceptin in HER2+ Patients, in Metastatic Breast Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 136 (actual)
- Sponsor
- US Oncology Research · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the ORR associated with Doxil in combination with carboplatin in HER2- (negative) MBC (and with Herceptin in HER2+ MBC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pegylated liposomal doxorubicin | 30 mg/m2 IV on Day 1 of each 28 day cycle |
| DRUG | Carboplatin | AUC=5 on Day 1 of each 28 day cycle |
| DRUG | trastuzumab | 4 mg/kg on Days 1 and 15 of each cycle(loading dose of 8 mg/kg on Day 1 of Cycle 1 only) |
Timeline
- Start date
- 2005-12-01
- Primary completion
- 2010-03-01
- Completion
- 2011-06-01
- First posted
- 2006-03-15
- Last updated
- 2016-11-03
- Results posted
- 2016-11-03
Locations
57 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00303108. Inclusion in this directory is not an endorsement.